Gilead
9 articles
Gilead: Stop Blocking Access to Hepatitis C Treatment
Thousands of activists urge company to change its policies on eve of shareholder meeting
On the eve of Gilead’s annual shareholder meeting, thousands of activists have demanded that Gilead change its policies that deny access to treatment for millions in developing countries. More
Hepatitis C: Gilead Patent on Sofosbuvir Partially Maintained Following MdM Patent Opposition
Paris, 5 October 2016
European Patent Office (EPO) has taken its decision following Médecins du Monde (MdM) patent opposition on Gilead’s sofosbuvir. MdM applauds EPO’s decision to revoke partially the patent. More
Gilead’s Claim That Generic Purchase of Sofosbuvir Would Lead to Patent Infringement in Brazil Dismissed
Gilead claims there is a patent infringement by two generic producers and directly asked to block any eventual commercialization of sofosbuvir products by these producers in Brazil. More
Gilead’s Claim That Generic Purchase of Sofosbuvir Would Lead to Patent Infringement in Brazil Dismissed
Gilead claims there is a patent infringement by two generic producers and directly asked to block any eventual commercialization of sofosbuvir products by these producers in Brazil. More